2018
DOI: 10.1016/j.cell.2018.03.033
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The Cancer Genome Atlas (TCGA) has catalyzed systematic characterization of diverse genomic alterations underlying human cancers. At this historic junction marking the completion of genomic characterization of over 11,000 tumors from 33 cancer types, we present our current understanding of the molecular processes governing oncogenesis. We illustrate our insights into cancer through synthesis of the findings of the TCGA PanCancer Atlas project on three facets of oncogenesis: (1) somatic driver mutations, germli… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
224
0
6

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 274 publications
(233 citation statements)
references
References 101 publications
(81 reference statements)
3
224
0
6
Order By: Relevance
“…The Pan-Cancer Atlas provides a panoramic view of the oncogenic processes that contribute to human cancer. It reveals how genetic variants collaborate in cancer progression and explores the influence of mutations on cell signaling and immune cell composition, providing insight to prioritize the development of new immunotherapies 144 .…”
Section: The Pan-cancer Atlas: Germline Pathogenic Variantsmentioning
confidence: 99%
“…The Pan-Cancer Atlas provides a panoramic view of the oncogenic processes that contribute to human cancer. It reveals how genetic variants collaborate in cancer progression and explores the influence of mutations on cell signaling and immune cell composition, providing insight to prioritize the development of new immunotherapies 144 .…”
Section: The Pan-cancer Atlas: Germline Pathogenic Variantsmentioning
confidence: 99%
“…We also found clonal indels in NF2 in two tumors (cdRCC and mixRCC), and MET (mixRCC), SMARCB1 (pRCC1) and ROS1 (pRCC2) indels in one tumor each. We found no mutations in TP53, mutated in a high proportion of cases across cancer types 15 , and no mutations in the 5'UTR region of TERT, which has been reported as mutated in a sizeable fraction of ccRCC 10 (Fig.1c and Fig. S2 and Table S5 and Table S6).…”
Section: Mutation Rates Frequency Of Driver Mutations and Germline mentioning
confidence: 51%
“…Other studies map the mutation landscape during oncogenesis with respect to the context-depending impact of a mutation on different gene regulatory levels, e.g. epigenome and transcriptome [56], or provided a unique clustering of tumor types and subtypes using multi-omic datasets [57]. …”
Section: Proteogenomics Across Populations Of Cancer Patientsmentioning
confidence: 99%